Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | DY3K7 | — |
received the Boostrix vaccine that is usually recommended when they are older, and patient was 22 months old; received Boostrix instead of Daptacel; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 22-month-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number DY3K7, expiry date 14-JUN-2027) for prophylaxis. Co-suspect products included Diphtheria vaccine toxoid, Pertussis vaccine acellular, Tetanus vaccine toxoid (Daptacel) for prophylaxis. On 29-JUL-2025, the patient received Boostrix. The patient did not receive Daptacel. On 29-JUL-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: received the Boostrix vaccine that is usually recommended when they are older, and patient was 22 months old) and wrong vaccine administered (Verbatim: received Boostrix instead of Daptacel). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-JUL-2025 The certified medical assistant reported they have a patient that had received the Boostrix vaccine that was usually recommended when they were older and patient was 22 months old, so they were just making sure that there was nothing that they need to do or no contradictions or anything like that with her, giving the vaccine at 22 months old instead of eleven. The patient received Boostrix instead of Daptacel earlier than the recommended age, which led to an inappropriate age at vaccine administration and wrong vaccine administered.